Financial Results at Ipsen | Detailed Financial Performance

Financial Results

Latest Financial Results

Filter

Period

Filter by

recent search

Reset

Showing: 1 – 05 of 29 Financial Results

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
 –  25 July 2024

25 July 2024

Download
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

PARIS, FRANCE, 25 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024.


Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
 –  24 April 2024

24 April 2024

Download
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.


Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
 –  08 February 2024

08 February 2024

Download
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.


Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
 –  26 October 2023

26 October 2023

Download
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.


Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
 –  27 July 2023

27 July 2023

Download
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance. We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions. I am confident, as…


Your dedicated contacts